SK Bioscience (Korea) Investor Sentiment

302440 Stock   47,100  2,000  4.07%   
About 61% of SK Bioscience's investor base is looking to short. The analysis of current outlook of investing in SK Bioscience Co suggests that many traders are alarmed regarding SK Bioscience's prospects. The current market sentiment, together with SK Bioscience's historical and current headlines, can help investors time the market. In addition, many technical investors use SK Bioscience stock news signals to limit their universe of possible portfolio assets.
  
over two months ago at news.google.com         
SK bioscience to acquire future equity in U.S. biotech firm Sunflower Therapeutics - MSN
Google News at Macroaxis
over three months ago at news.google.com         
SK Bioscience Sells Part of Novavax Stake for 20 Billion Won, but Maintaining Strategic Partnership ...
Google News at Macroaxis
over three months ago at news.google.com         
SK Bioscience to acquire Klockes CDMO in cross-holding MA - BioWorld Online
Google News at Macroaxis
over three months ago at news.google.com         
SK Biosciences Stock Soars 8 percent Following Acquisition of German Vaccine CMO Company -
Google News at Macroaxis
over three months ago at news.google.com         
SK Bioscience Shares Surge After Acquisition Plan - MarketWatch
Google News at Macroaxis
over six months ago at news.google.com         
The stock price is weak for a long time as pharmaceutical and bio companies, which had surged due to...
Google News at Macroaxis
over six months ago at news.google.com         
SK bioscience devises new business strategy for post-pandemic era - koreatimes
Google News at Macroaxis
over six months ago at news.google.com         
SK bioscienceLtds Weak Earnings May Only Reveal A Part Of The Whole Picture - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
Manufacturing facility expansion to advance next-gen vaccine - Marketscreener.com
Google News at Macroaxis
over six months ago at news.google.com         
How Did SK bioscience Co.,Ltd.s 2.7 percent ROE Fare Against The Industry - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
SK bioscience Receives WHO Prequalification for Typhoid Conjugate Vaccine - Yahoo Finance
Google News at Macroaxis
over six months ago at news.google.com         
SK Biosciences Net Income Plunges in Q4 -February 02, 2024 at 0647 am EST - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Novavaxs Updated COVID-19 Vaccine Receives Emergency Use Authorization in the Republic of Korea - Bu...
Google News at Macroaxis
over a year ago at news.google.com         
Postpartum Depression Market to Exhibit Positive Growth During the ... - InvestorsObserver
Google News at Macroaxis
over a year ago at news.google.com         
Comparative genomics and genome-wide SNPs of endangered ... - Nature.com
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about SK Bioscience that are available to investors today. That information is available publicly through 302440 media outlets and privately through word of mouth or via 302440 internal channels. However, regardless of the origin, that massive amount of 302440 data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of SK Bioscience news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of SK Bioscience relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to SK Bioscience's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive SK Bioscience alpha.

SK Bioscience Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for 302440 Stock analysis

When running SK Bioscience's price analysis, check to measure SK Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SK Bioscience is operating at the current time. Most of SK Bioscience's value examination focuses on studying past and present price action to predict the probability of SK Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SK Bioscience's price. Additionally, you may evaluate how the addition of SK Bioscience to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk